Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

358 ARTÍCULOS , VIENDO DEL 121 AL 135

Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's Disease

Panza F, Solfrizzi V, Seripa D, Imbimbo BP, Lozupone M, Santamato A, Zecca C, Barulli MR, Bellomo A, Pilotto A, Daniele A, Greco A, Logroscino G.

Biomed Res Int. 2016;2016:3245935. doi: 10.1155/2016/3245935. Epub 2016 Jun 26.

Changes in insulin and insulin signaling in Alzheimer's disease: cause or consequence?

Stanley M, Macauley SL, Holtzman DM.

J Exp Med. 2016 Jul 25;213(8):1375-85. doi: 10.1084/jem.20160493. Epub 2016 Jul 18.

Pharmacotherapeutic strategies in the treatment of severe Alzheimer's disease

Deardorff WJ, Grossberg GT.

Expert Opin Pharmacother. 2016 Sep;17(13):1789-800. doi: 10.1080/14656566.2016.1215431. Epub 2016 Jul 29.

Potential Therapeutic Effects of Oleuropein Aglycone in Alzheimer's Disease

Martorell M, Forman K, Castro N, Capó X, Tejada S, Sureda A.

Curr Pharm Biotechnol. 2016;17(11):994-1001. doi: 10.2174/1389201017666160725120656.

Old and new acetylcholinesterase inhibitors for Alzheimer's disease

Galimberti D, Scarpini E.

Expert Opin Investig Drugs. 2016 Oct;25(10):1181-7. doi: 10.1080/13543784.2016.1216972. Epub 2016 Aug 5.

[Progress of clinical trials in Alzheimer’s disease drugs]

Peng Y, Li PP, Li L, Zhang Y, Hou WZ, Cui DD, Li J, Wang L, Wang QL, Wang XL.

Yao Xue Xue Bao. 2016 Aug;51(8):1185-95.

Adenosine Type A2A Receptor in Peripheral Cell from Patients with Alzheimer's Disease, Vascular Dementia, and Idiopathic Normal Pressure Hydrocephalus: A New/Old Potential Target

Arosio B, Casati M, Gussago C, Ferri E, Abbate C, Scortichini V, Colombo E, Rossi PD, Mari D.

J Alzheimers Dis. 2016 Sep 6;54(2):417-25. doi: 10.3233/JAD-160324.

Editorial (Thematic Issue: Old Facts and New Perspectives to Face Alzheimer's Dementia. Focus on Non Neuronal Participants to Neurodegeneration)

Martorana A, Silvestrini M.

CNS Neurol Disord Drug Targets. 2016;15(6):646. doi: 10.2174/1871527315999160606154409.

Treatment strategies in Alzheimer's disease: a review with focus on selenium supplementation

Aaseth J, Alexander J, Bjørklund G, Hestad K, Dusek P, Roos PM, Alehagen U.

Biometals. 2016 Oct;29(5):827-39. doi: 10.1007/s10534-016-9959-8. Epub 2016 Aug 16.

Editorial (Thematic Issue: Current and Perspective Therapeutic Strategies for Alzheimer's Disease)

Piccionello AP, Cappello F.

Curr Pharm Des. 2016;22(26):3935-6. doi: 10.2174/138161282226160801224800.

The Anti-Inflammatory Role of Minocycline in Alzheimer´s Disease

Budni J, Garcez ML, de Medeiros J, Cassaro E, Bellettini-Santos T, Mina F, Quevedo J.

Curr Alzheimer Res. 2016;13(12):1319-1329. doi: 10.2174/1567205013666160819124206.

Editorial: Combining Forces to Improve Alzheimer's Disease Drug Discovery: The Symptomatic Battle

Deguil J, Auffret A, Schenker E, Aujard F, Lamberty Y, Bartrès-Faz D, Blin O, Micallef J, Richardson JC, Bordet R.

CNS Neurol Disord Drug Targets. 2016;15(7):754-5. doi: 10.2174/187152731507160808200737.

Perspectives for treating Alzheimer's disease: a review on promising pharmacological substances

Cazarim Mde S, Moriguti JC, Ogunjimi AT, Pereira LR.

Sao Paulo Med J. 2016 Jul-Aug;134(4):342-54. doi: 10.1590/1516-3180.2015.01980112.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias